Brief: Acumen Pharmaceuticals Announces Nomination Of Two Enhanced Brain Delivery™ (Ebd™) Development Candidates For The Treatment Of Alzheimer’S Disease
16/06/2026 13:44
BRIEF-Acumen Pharmaceuticals Announces Nomination Of Two Enhanced Brain Delivery™ (Ebd™) Development Candidates For The Treatment Of Alzheimer’S Disease June 16 (Reuters) - Acumen Pharmaceuticals Inc ABOS.O:
ACUMEN PHARMACEUTICALS ANNOUNCES NOMINATION OF TWO ENHANCED BRAIN DELIVERY™ (EBD™) DEVELOPMENT CANDIDATES FOR THE TREATMENT OF ALZHEIMER’S DISEASE
Source text: ID:nGNX9JT11k
Further company coverage: ABOS.O
((Reuters.Briefs@thomsonreuters.com;))